SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

KULR Technology Group, Inc. engages in developing, manufacturing, and licensing next-generation carbon fiber thermal management technologies for batteries and electronic systems. Its products include cellcheck, safecase, thermal capacitor, fiber thermal interface, thermal runaway shield, internal short circuit, and cathode. The company was founded by Michael Mo and Timothy R. Knowles in December 2015 and is headquartered in Webster, TX.

KULR Technology Group Inc

KULR is trending due to a recent launch of its next-generation Battery Management System (kBMS) for defense and space applications, sparking bullish sentiment. The community is discussing the potential for a short squeeze and the company's Bitcoin treasury strategy. Some investors view KULR as a "picks and shovels" play in the growing battery and energy storage sector, while others express concern over dilution and past performance.

Hillenbrand, Inc. is a global industrial company, which engages in providing engineered processing equipment and solutions. It operates through the Advanced Process Solutions and Molding Technology Solutions segments. The Advanced Process Solutions segment provides compounding, extrusion, and material handling, screening, and separating equipment, systems, and services for manufacturing and other industrial processes. The Molding Technology Solutions segment includes engineered and customized equipment, systems, and services in plastic technology and processing. It also operates through the following geographical segments: United States, China, India, Germany, and All Other Countries. The company was founded on November 1, 2007 and is headquartered in Batesville, IN.

Hillenbrand Inc

Hillenbrand is trending due to recent strategic moves, including considering a potential sale of the company's plastics division and exploring strategic alternatives for its Batesville business. Unusual options activity suggests bullish sentiment, while the community discusses the company's consolidation and potential for a significant move. Wall Street's EPS expectations and recent insider activity are also being closely monitored.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community celebrates its recent listing on Robinhood, anticipating increased exposure and potential price growth. Discussions revolve around Floki's long-term potential, comparisons to other meme coins, and predictions for a significant rally. Some community members highlight Floki's ecosystem and utility, differentiating it from other meme coins.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

Satoshi Nakamoto ($SATOSHI) is trending as the community celebrates its anniversary and touts it as the 'Bitcoin of memes'. Discussions revolve around its timeless narrative, strong community, and potential for massive growth due to its association with the pseudonymous creator of Bitcoin. Many believe $SATOSHI embodies the identity of the entire crypto industry.

First Horizon Corp. (Tennessee) operates as a financial holding company, which engages in the provision of checking accounts, savings products, mortgage banking, lending, and financing to individuals and businesses. It operates the business through three segments: Regional Banking, Specialty Banking, and Corporate. The Regional Banking segment offers financial products and services, including traditional lending and deposit taking, to retail and commercial customers. The Specialty Banking segment consists of lines of business that deliver product offerings and services with specialized industry knowledge. The Corporate segment focuses on corporate support functions such as risk management, audit, accounting, finance, executive office, and corporate communications. The company was founded by Frank S. Davis in 1864 and is headquartered in Memphis, TN.

First Horizon Corporation

First Horizon is trending due to unusual options activity and analyst rating adjustments, sparking discussions about its potential. Community talking points include speculation about future performance, potential acquisitions, and comparison to other regional banks. The stock's movements are also being analyzed in the context of broader sector trends and interest rate sensitivity.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics is trending as investors speculate about a potential acquisition, fueled by unusual options activity and a recent technical breakout on the charts. Community members are weighing positive regulatory and revenue updates against insider selling, while others discuss potential M&A scenarios in the pharmaceutical sector. Upcoming catalysts, including a PDUFA decision in October, are adding to the heightened interest in $ARQT.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending amid increasing excitement surrounding the potential FDA approval of Afrezza for pediatric use and the upcoming close of the scPharmaceuticals acquisition, with revenue growth anticipated. The community is buzzing about potential double-digit stock prices, and an anticipated SNDA submission for the Furoscix autoinjector. Some investors are looking ahead to potential partnerships and future catalysts, while acknowledging the long-term investment.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its association with cannabis culture and positions it as a cryptocurrency with a unique identity. The community emphasizes the cultural significance and longevity of the "weed culture". Some users are comparing Weedcoin to Bitcoin.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Instacart ($CART) is trending due to analyst rating changes and community discussions around competition in the grocery delivery space. Analysts are split, with some downgrading the stock due to increased competition from Amazon, DoorDash, and Uber, while others remain bullish, citing strong fundamentals and growth potential. The community is actively debating the company's valuation, competitive advantages, and potential for a takeover.

Trump For President

Trump Crypto is trending amidst mixed sentiment and volatility, with some community members labeling it a "shitcoin" while others express optimism about potential gains. Discussions also involve broader topics like potential interest rate cuts, government shutdowns, and the connection between crypto and political figures. The community is actively debating the coin's future and its relationship with other cryptocurrencies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Petros Pharmaceuticals sank to an all-time low on Wednesday after the company enacted a 1-for-25 reverse stock split, triggering a wave of retail investor chatter and raising fresh concerns about its Nasdaq listing status.The split, which became effective after markets closed Wednesday, aimed to lift Petros’ share price above Nasdaq’s $1 minimum bid requirement.&nbsp;While the maneuver shrank the company’s outstanding share count from roughly 53.5 million to about 2.14 million, it failed to stabilize investor sentiment.&nbsp;Shares tumbled more than 30% intraday Thursday, hitting a split-adjusted low of $0.012 — the stock’s lowest level since its 2020 debut.Despite the steep sell-off, sentiment among retail investors turned “extremely bullish” on Stocktwits amid “extremely high” message volume.One user said, “Given the incentive to exercise at no cost, they may use the remaining shares to drive the price down further,” adding that volume needed to hit at least 30 million before considering a position.&nbsp;<stembedurl>https://stocktwits.com/basijedal/message/613198834</stembedurl>Another said the reverse split “might actually be positive,” citing the post-split price as potentially attractive to speculators. “It probably will still be volatile and could go up,” they added.<stembedurl>https://stocktwits.com/1Black/message/613194524</stembedurl>The steep decline comes as Petros continues to face the risk of delisting from the Nasdaq Capital Market, after previously receiving a noncompliance notice related to minimum stockholders' equity requirements.In parallel, the company is pivoting from its legacy men’s health products toward regulatory-aligned digital health solutions.&nbsp;Petros is developing a software-as-a-medical-device platform that leverages AI and big data to assist pharmaceutical companies with converting prescription drugs to over-the-counter status.&nbsp;Management positioned this strategy as well-timed following President Trump’s April 15 executive order titled&nbsp;“Lowering Drug Prices by Once Again Putting Americans First”—a policy Petros says supports its market transition.“This Executive Order supports the notion that the under-insured and the American population at large will benefit from expanded access to certain drugs,” said Chief Commercial Officer Fady Boctor.&nbsp;He added that Petros’ platform could unlock partnerships with pharmaceutical firms aiming to extend their product lifecycles and reduce drug prices.But questions remain about the company’s financial health.&nbsp;For the year ended Dec. 31, 2024, Petros reported revenue of $5.11 million, down from $5.82 million in 2023.&nbsp;Net losses widened to $14.32 million from $8.16 million, even as loss per share narrowed to $3.34 from $6.35 due to a higher share count.Petros shares have tumbled over 99.9% year-to-date, far underperforming the Dow Jones, down 4.1%, the S&amp;P 500, down 5.1%, and the Nasdaq, down 1.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on April 30, 2025 in New York City. (Photo by Michael M. Santiago/Getty Images)

Petros Pharma Stock Plunges To Record Low On 1-For-25 Reverse Split, But Retail Optimism Lingers

Petros Pharmaceuticals hit an all-time low after a 1-for-25 reverse stock split, drawing bullish retail chatter even as delisting risks and mounting losses weighed on the stock.

Equity

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI Research Report) yesterday. The company's shares closed ye...

EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says

Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the...

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56...

Petros Pharmaceuticals (NASDAQ:PTPI) & Liberty Health Sciences (OTCMKTS:LHSIF) Critical Review

Liberty Health Sciences (OTCMKTS:LHSIF - Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will...

Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC...

Petros Pharmaceuticals enters AI-licensing agreement with software provider

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch

FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Petros Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.0247
Prev Close	$0.0243
Open	$0.0238
Dividend Yield	0.00%
50-Day Moving Average	$0.0284
Beta	0.64
Avg. Volume	374,411.81
PE Ratio	0.00

52-Week High	$16.25
52-Week Low	$0.0226
Market Capitalization	$1.03M
EPS (Annual)	-$83.47
Price to Book	0.23
Revenue Per Employee	$284,002.39
Enterprise Value/EBITDA	N/A

PTPI
Petros Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PTPI News

PTPI Petros Pharmaceuticals Inc